Publicacions en col·laboració amb investigadors/es de Gustave Roussy Cancer Campus (17)

2024

  1. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

2023

  1. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

    The oncologist, Vol. 28, Núm. 3, pp. 258-267

  2. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

    Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476

2022

  1. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1404-1414

2021

  1. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

    Clinical Cancer Research, Vol. 27, Núm. 4, pp. 992-1003

2020

  1. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

    Lung Cancer, Vol. 146, pp. 6-11

  2. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer

    Lung Cancer, Vol. 142, pp. 63-69

  3. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 271-282

  4. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 135, pp. 74-77

  2. Erratum to “Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts” [Radiother. Oncol. 135 (2019) 74–77](S0167814019300775)(10.1016/j.radonc.2019.02.010)

    Radiotherapy and Oncology

  3. Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

    Clinical Lung Cancer, Vol. 20, Núm. 4, pp. 305-312.e3

  4. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

    Journal of Thoracic Oncology, Vol. 14, Núm. 10, pp. 1828-1838

  5. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

    Annals of Oncology

  6. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166

2018

  1. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

    JAMA Oncology, Vol. 4, Núm. 3, pp. 351-357

2016

  1. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial

    Annals of Oncology, Vol. 27, Núm. 3, pp. 417-423